Press coverage about Boston Scientific (NYSE:BSX) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 45.6730989115198 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Boston Scientific Closes Acquisition of Claret Medical, Inc., Announces Positive Reimbursement Decision (newkerala.com)
- See what the IHS Markit Score report has to say about Boston Scientific Corp. (finance.yahoo.com)
- Electrophysiology Market Global Share 2018: St. Jude Medical Inc, Boston Scientific Corporation, Biosense Webster … (realcriticism.com)
- Global Cardiac Resynchronization Therapy System Market 2018 – Abbott, Boston Scientific Corporation, BIOTRONIK … (thechronicleindia.com)
- Most Active Stock: Boston Scientific Corporation (BSX), Church & Dwight Co. (CHD) (newsregistrar.com)
A number of brokerages have recently commented on BSX. Raymond James increased their price objective on Boston Scientific from $32.00 to $34.00 and gave the company a “strong-buy” rating in a report on Thursday, April 26th. Zacks Investment Research raised Boston Scientific from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a report on Friday, May 11th. Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Boston Scientific in a report on Wednesday, April 25th. ValuEngine raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Monday, June 11th. Finally, Royal Bank of Canada increased their target price on Boston Scientific to $36.00 and gave the company a “top pick” rating in a research note on Monday, July 23rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $34.95.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 25th. The medical equipment provider reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.07. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The company had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter last year, the company earned $0.32 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. equities research analysts forecast that Boston Scientific will post 1.38 EPS for the current year.
In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $33.66, for a total value of $168,300.00. Following the completion of the sale, the executive vice president now owns 29,201 shares in the company, valued at approximately $982,905.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David A. Pierce sold 1,650 shares of the firm’s stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $30.83, for a total value of $50,869.50. The disclosure for this sale can be found here. Insiders sold a total of 157,986 shares of company stock valued at $5,244,475 in the last quarter. Corporate insiders own 0.73% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: Diversification in Investing
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.